Pfizer: FDA panel backs approval of ulcerative colitis drug
(CercleFinance.com) - A US advisory panel has recommended approval of Pfizer's Xeljanz for the treatment of adult patients with moderate-to-severely active ulcerative colitis, the company said on Friday.
Pfizer announced a positive outcome from an FDA committee that was intended to discuss a supplemental new drug application (sNDA) for this first oral therapy designed for adults living with this debilitating, difficult-to-control disease.
FDA's decision on whether or not to approve the experimental drug is expected in June.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Pfizer announced a positive outcome from an FDA committee that was intended to discuss a supplemental new drug application (sNDA) for this first oral therapy designed for adults living with this debilitating, difficult-to-control disease.
FDA's decision on whether or not to approve the experimental drug is expected in June.
Copyright (c) 2018 CercleFinance.com. All rights reserved.